Baseline characteristics of the study patients (N = 595)
| Characteristic . | All patients (N = 595) . | Beat-AML 2024 ELN-refined model (n = 579)∗ . | P value . | ||
|---|---|---|---|---|---|
| Beat-AML favorable (n = 127) . | Beat-AML intermediate (n = 238) . | Beat-AML adverse (n = 214) . | |||
| Age, median (range), y | 73 (60-92) | 74 (60-89) | 74 (60-92) | 73 (60-89) | .159 |
| Female sex, n (%) | 247 (42) | 67 (53) | 85 (36) | 88 (41) | .007 |
| Ethnicity, n (%)† | .021 | ||||
| Hispanic | 7 (1) | 4 (3) | 2 (1) | 0 (0) | |
| Non-Hispanic | 560 (94) | 122 (94) | 226 (94) | 205 (96) | |
| Race, n (%)† | |||||
| White | 463 (78) | 97 (76) | 190 (80) | 165 (77) | .871 |
| African American | 32 (5) | 7 (6) | 11 (5) | 14 (7) | |
| Asian | 15 (3) | 5 (4) | 6 (3) | 4 (2) | |
| Multiple or other | 43 (7) | 9 (7) | 15 (6) | 16 (7) | |
| Cytogenetics, n (%)†,,‡ | |||||
| Normal karyotype | 198 (33) | 88 (69) | 86 (36) | 19 (9) | <.001 |
| Complex karyotype | 199 (33) | 1 (0) | 40 (17) | 152 (71) | <.001 |
| Chromosome 5/5q abnormality | 134 (23) | 0 (0) | 21 (9) | 110 (52) | <.001 |
| Chromosome 7 abnormality | 129 (22) | 3 (2) | 35 (15) | 88 (41) | <.001 |
| Chromosome 17 abnormality | 4 (1) | 0 (0) | 1 (0) | 3 (1) | .244 |
| Core-binding factor | 10 (3) | 9 (7) | 0 (0) | 0 (0) | <.001 |
| KMT2A-rearrangement | 18 (3) | 6 (5) | 6 (3) | 6 (3) | .496 |
| Mutation, n (%)§ | |||||
| TP5 | 175 (29) | 3 (2) | 7 (3) | 160 (75) | <.001 |
| IDH2 | 112 (19) | 42 (33) | 64 (27) | 3 (1) | <.001 |
| MLL2 | 98 (16) | 19 (15) | 8 (3) | 69 (32) | <.001 |
| KRAS | 40 (7) | 7 (6) | 2 (1) | 29 (14) | <.001 |
| RUNX1 | 146 (25) | 2 (2) | 103 (43) | 37 (17) | <.001 |
| DNMT3A | 143 (24) | 53 (42) | 60 (25) | 26 (12) | <.001 |
| TET2 | 139 (23) | 24 (19) | 73 (31) | 37 (17) | .002 |
| ASXL1 | 137 (23) | 7 (6) | 94 (39) | 33 (15) | <.001 |
| SRSF2 | 136 (23) | 17 (14) | 92 (39) | 26 (12) | <.001 |
| NRAS | 91 (15) | 21 (17) | 41 (17) | 26 (12) | .249 |
| NPM1 | 90 (15) | 74 (58) | 9 (4) | 3 (1) | <.001 |
| FLT3-ITD | 71 (12) | 29 (23) | 29 (12) | 8 (4) | <.001 |
| STAG2 | 62 (10) | 3 (2) | 49 (21) | 10 (5) | <.001 |
| IDH1 | 54 (9) | 21 (17) | 23 (10) | 10 (5) | .001 |
| BCOR | 52 (9) | 0 (0) | 29 (12) | 20 (9) | <.001 |
| U2AF1 | 49 (8) | 0 (0) | 32 (13) | 15 (7) | <.001 |
| SF3B1 | 47 (8) | 1 (1) | 25 (11) | 19 (9) | .003 |
| EZH2 | 35 (6) | 3 (2) | 23 (10) | 7 (3) | .003 |
| ZRSR2 | 25 (4) | 1 (1) | 12 (5) | 12 (6) | .082 |
| Characteristic . | All patients (N = 595) . | Beat-AML 2024 ELN-refined model (n = 579)∗ . | P value . | ||
|---|---|---|---|---|---|
| Beat-AML favorable (n = 127) . | Beat-AML intermediate (n = 238) . | Beat-AML adverse (n = 214) . | |||
| Age, median (range), y | 73 (60-92) | 74 (60-89) | 74 (60-92) | 73 (60-89) | .159 |
| Female sex, n (%) | 247 (42) | 67 (53) | 85 (36) | 88 (41) | .007 |
| Ethnicity, n (%)† | .021 | ||||
| Hispanic | 7 (1) | 4 (3) | 2 (1) | 0 (0) | |
| Non-Hispanic | 560 (94) | 122 (94) | 226 (94) | 205 (96) | |
| Race, n (%)† | |||||
| White | 463 (78) | 97 (76) | 190 (80) | 165 (77) | .871 |
| African American | 32 (5) | 7 (6) | 11 (5) | 14 (7) | |
| Asian | 15 (3) | 5 (4) | 6 (3) | 4 (2) | |
| Multiple or other | 43 (7) | 9 (7) | 15 (6) | 16 (7) | |
| Cytogenetics, n (%)†,,‡ | |||||
| Normal karyotype | 198 (33) | 88 (69) | 86 (36) | 19 (9) | <.001 |
| Complex karyotype | 199 (33) | 1 (0) | 40 (17) | 152 (71) | <.001 |
| Chromosome 5/5q abnormality | 134 (23) | 0 (0) | 21 (9) | 110 (52) | <.001 |
| Chromosome 7 abnormality | 129 (22) | 3 (2) | 35 (15) | 88 (41) | <.001 |
| Chromosome 17 abnormality | 4 (1) | 0 (0) | 1 (0) | 3 (1) | .244 |
| Core-binding factor | 10 (3) | 9 (7) | 0 (0) | 0 (0) | <.001 |
| KMT2A-rearrangement | 18 (3) | 6 (5) | 6 (3) | 6 (3) | .496 |
| Mutation, n (%)§ | |||||
| TP5 | 175 (29) | 3 (2) | 7 (3) | 160 (75) | <.001 |
| IDH2 | 112 (19) | 42 (33) | 64 (27) | 3 (1) | <.001 |
| MLL2 | 98 (16) | 19 (15) | 8 (3) | 69 (32) | <.001 |
| KRAS | 40 (7) | 7 (6) | 2 (1) | 29 (14) | <.001 |
| RUNX1 | 146 (25) | 2 (2) | 103 (43) | 37 (17) | <.001 |
| DNMT3A | 143 (24) | 53 (42) | 60 (25) | 26 (12) | <.001 |
| TET2 | 139 (23) | 24 (19) | 73 (31) | 37 (17) | .002 |
| ASXL1 | 137 (23) | 7 (6) | 94 (39) | 33 (15) | <.001 |
| SRSF2 | 136 (23) | 17 (14) | 92 (39) | 26 (12) | <.001 |
| NRAS | 91 (15) | 21 (17) | 41 (17) | 26 (12) | .249 |
| NPM1 | 90 (15) | 74 (58) | 9 (4) | 3 (1) | <.001 |
| FLT3-ITD | 71 (12) | 29 (23) | 29 (12) | 8 (4) | <.001 |
| STAG2 | 62 (10) | 3 (2) | 49 (21) | 10 (5) | <.001 |
| IDH1 | 54 (9) | 21 (17) | 23 (10) | 10 (5) | .001 |
| BCOR | 52 (9) | 0 (0) | 29 (12) | 20 (9) | <.001 |
| U2AF1 | 49 (8) | 0 (0) | 32 (13) | 15 (7) | <.001 |
| SF3B1 | 47 (8) | 1 (1) | 25 (11) | 19 (9) | .003 |
| EZH2 | 35 (6) | 3 (2) | 23 (10) | 7 (3) | .003 |
| ZRSR2 | 25 (4) | 1 (1) | 12 (5) | 12 (6) | .082 |
Genes highlighted in bold were included in the final risk stratification model
The final model is restricted to patients with reported outcome data (579/595).
Unknown values were not considered in P value calculations and are excluded from the results.
Mutations were considered present at any detectable VAF.
Cytogenetics available for 588/595.